Articles related to MYELODYSPLASTIC SYNDROMES

Discover why CPX-351 extends relapse-free survival but does not significantly alter overall survival in younger AML/MDS patients, as revealed by the UK NCRI AML19 trial.

Enhance your clinical decision-making skills in the management of ESA-refractory LR-MDS. Register now for actionable insights and the latest research findings.

Luspatercept demonstrated superiority over epoetin alfa in improving red blood cell (RBC) transfusion independence in transfusion-dependent patients with lower-risk myelodysplastic syndromes (LR-MDS) who have not previously received erythropoiesis-stimulating agents (ESAs). These findings are part of a study that was presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting:

Nutritional challenges are common in older adults with acute leukemia (AML/MDS), and can have a significant impact on their quality of life and treatment outcomes. These challenges can be caused by a variety of factors, including the disease itself, its treatment, and the normal aging process. Some of the most common nutritional challenges in older adults with AML/MDS include appetite loss, weight loss, diarrhea, constipation, and mouth sores; physicians can provide nutritional interventions to help address these challenges and improve the quality of life for older adults with AML/MDS. These interventions may include nutrition counseling, meal planning, supplementation, and enteral nutrition.

In patients with R/R MDS/AML, the combination ipilimumab + decitabine (IPI + DEC) therapy shows a favorable safety profile and significant therapeutic activity that doesn’t seem to require T cell-mediated alloreactivity. Potential transplant candidates may find that IPI + DEC therapy acts as a less strenuous transition to transplant. Future research is necessary to determine logical IPI-based treatment plans that can provide persistent responses without causing significant immune damage.

Hematologist-oncologists, hematology-oncology NP/PAs, hematology-oncology nurses, and pharmacists should be better able to use criteria for erythroid-stimulating agent (ESA) failure to hasten the identification of patients with lower-risk myelodysplastic syndrome (MDS) refractory to ESA therapy, integrate safety and efficacy data on emerging therapeutic options into treatment planning for patients with lower-risk MDS after ESA failure, and integrate a multidisciplinary treatment approach after taking part in this CME activity.